Technology ID
TAB-2079

Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases

E-Numbers
E-308-2009-0
Lead Inventor
Thomas, Craig (National Human Genome Research Institute (NIH/NHGRI))
Co-Inventors
Boxer, Matthew (National Human Genome Research Institute (NIH/NHGRI))
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Immunology
Development Status
Early stage
Lead IC
NCATS
Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Caspase 1 is known to play a pro-inflammatory role in numerous autoimmune and inflammatory diseases and therefore represents an excellent target for treatment of a broad range of diseases, including but not limited to Huntington's, amyotrophic lateral sclerosis, ischemia, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and sepsis. Not surprisingly this enormous potential has resulted in at least three caspase 1 inhibitors entering clinical trials (VX-740, IDN-6556, and VX-765) in recent years.
Commercial Applications
  • Potential therapeutic for a broad range of autoimmune diseases
  • Potential therapeutic for a broad range of inflammatory diseases
Licensing Contact:
Vepa, Suryanarayana
sury.vepa@nih.gov